Skip to content

PTSD: all studies

Page 12 of 210: studies 111 to 120 of 2,096, newest first. Back to the PTSD overview

Research

Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans.

Journal of Affective Disorders November 18, 2025 Randi Brown, Jennifer I. Lissemore, Kenneth Shinozuka et al. 1 citation

Ibogaine is an atypical psychedelic that evokes unique subjective effects, including mystical experiences. Mystical experiences have shown a mediating effect on clinical improvements following treatment with several psychedelic substances; however, the relationship between mystical experiences and clinical outcomes following ibogaine remains unclear. We examined the association between mystical...

DOI: 10.1016/j.jad.2025.120722 (opens in new tab) Full text (opens in new tab) PTSD Ibogaine-magnesium Mistic Peak alpha frequency +3

Comparative Efficacy of Psilocybin and MDMA in PTSD Treatment: A Systematic Review of Long-Term Outcomes

Berkeley Scientific Journal November 13, 2025 Presley Aspen

Highly stressful events can lead to post-traumatic stress disorder (PTSD)-a significant public health concern which existing treatments (e.g., psychotherapy and traditional medications) have shown marginal efficacy for.Psychedelics-alternatively called hallucinogens-are psychoactive substances that cause perception, mood, and cognitive changes.Because they are known for their impact on neuron...

MDMA-Assisted Psychotherapy for PTSD: A Systematic Review of Randomized Control Trials

Journal of Psychoactive Drugs November 5, 2025 B Brett, Christine Bynum 4 citations

Posttraumatic stress disorder (PTSD) is a serious and chronic mental health condition with limited effective treatment options. 3,4-methylenedioxymethamphethamine (MDMA)-assisted psychotherapy (MDMA-AT) has shown promise in phase 2 and phase 3 clinical trials, with many research participants reporting significant reductions in PTSD symptoms. However, the Federal Drug Administration (FDA)...

DOI: 10.1080/02791072.2025.2577308 (opens in new tab) MDMA Placebo Randomized controlled trial Posttraumatic stress +7

Ketamine Assisted EMDR Therapy™ for PTSD: investigating the synergistic effects of pharmacotherapy and psychotherapy

European Journal of Psychotraumatology November 4, 2025 Michele Topel, Donald S. Ciccone 2 citations

Background: Posttraumatic stress disorder (PTSD) is associated with maladaptive memory reconsolidation and overgeneralized fear responses. EMDR therapy promotes trauma reprocessing by activating the brain's intrinsic memory reconsolidation mechanism, facilitating memory updating, and abandoning outdated emotional schemas. Ketamine may also facilitate adaptive updating of traumatic memory due to...

DOI: 10.1080/20008066.2025.2572861 (opens in new tab) Ketamine Memory consolidation Clinical psychology Psychotherapist +6

Status of Imagery Rehearsal Therapy and Other Interventions for Nightmare Treatment in PTSD.

Current Psychiatry Reports November 1, 2025 Christine J So, Courtney J Bolstad, Katherine E Miller

We review the recent published literature on nightmare-focused interventions, including imagery rehearsal therapy, for trauma-exposed adult populations. Imagery rehearsal therapy (IRT) and prazosin remain the most supported treatments, though results vary across studies. New consensus guidelines have led to Cognitive Behavioral Therapy for Nightmares (CBT-N), which integrates rescripting,...

Epigenetic aging and DNA methylation biomarker changes following ketamine treatment in patients with MDD and PTSD: a pilot study.

Translational Psychiatry October 31, 2025 Kristin L Dawson, Athena May Jean M. Carangan, Jessica Klunder et al. 2 citations

Major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are debilitating psychiatric conditions associated with poor health outcomes similarly observed in non-pathological aging. Ketamine is a dissociative anesthetic and NMDA receptor antagonist with demonstrated rapid reduction in symptoms associated with Treatment Resistant Depression (TRD) and PTSD. Ketamine's effects on...

Evaluating the efficacy and safety of MDMA for the treatment of Post Traumatic Stress Disorder: a systematic review

UCC Student Medical Journal October 17, 2025 Megha Kodancha, Houssein Chahrour, Charles Carey et al.

Background: Posttraumatic stress disorder (PTSD) affects approximately 5-7% of the population, with conventional treatments often proving inadequate for some patients. Recent studies suggest that methylenedioxymethamphetamine (MDMA) combined with psychotherapy may offer a novel therapeutic approach. This systematic review evaluates the efficacy and safety of MDMA-assisted psychotherapy for the...

DOI: 10.33178/smj.2025.1.4 (opens in new tab) MDMA Traumatic stress Randomized controlled trial Clinical psychology +8

MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions

Psychedelics October 14, 2025 Mingming Zhao, Jianjun Yang, Kenji Hashimoto

MDMA, 3,4-methylenedioxymethamphetamine (“ecstasy,” “molly”), is a distinctive entactogen that reverses the serotonin (5-HT) transporter to increase synaptic 5-HT, while also engaging catecholaminergic and oxytocinergic pathways. In clinical trials, MDMA-assisted psychotherapy has yielded substantial improvements in treatment-resistant posttraumatic stress disorder (PTSD), although regulatory...

Questions and Concerns About MDMA-Assisted Therapy (MDMA-AT) in Veterans with PTSD Symptoms

Journal of Psychoactive Drugs October 10, 2025 Mitch Earleywine, Caitlin Holley, Henry A MacConnel et al.

MDMA-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) shows promise, but attitudes and beliefs about this treatment, especially in symptomatic veterans, remain poorly understood. We sought to explore relevant attitudes in veterans receiving healthcare from Veterans Affairs as a step toward designing relevant surveys or psychoeducation materials for future work. We employed a...

DOI: 10.1080/02791072.2025.2570938 (opens in new tab) Anxiety Psychoeducation Curiosity Narrative +11

Mindfulness-Based Intervention Improves Depression, Anxiety, and Quality of Life in Unstably-Housed Women with PTSD and Substance Use Disorder

Mindfulness October 1, 2025 Dana Rose Garfin, Cordelia Lee, Branislav Jovanovic et al.

Abstract Objective This study sought to evaluate the efficacy of Mindfulness-based Stress Reduction (MBSR) on symptoms of posttraumatic stress, depression, anxiety, and perceived stress and quality of life in unstably-housed women undergoing substance use disorder (SUD) treatment. Despite the potential for MBSR to be a helpful adjunct to ongoing care, prior research on the benefit of MBSR in...